Pharmaceutical Market Trends, 2007-2011

Key market forecasts and growth opportunities (2nd Edition)

Publication Date	November 2007
Publisher	URCH Publishing
Product Type	Report
Pages	173
ISBN Number	978-1-905751-06-8
Product Code	URC00017

Buy this product or for assistance call +44 20 7060 7474

PDF £995.00$1655 | €1114

PRINT £1,050.00$1747 | €1175

FAX Order above formats by FAX

Summary

"The global pharmaceutical market grew to US$643 billion in 2006, growing at a compound annual growth rate (CAGR) of 10.0% between 1999 and 2006. However, year-on-year growth slowed to 6.8% in 2006, largely as a result of increased competition from generic products and the effects of continued healthcare cost containment across major markets."

Pharmaceutical Market Trends, 2007 - 2011: Key market forecasts & growth opportunities presents a detailed trend analysis of the global pharmaceutical market as at the end of 2006 and forecasts until 2011. The 173 page report presents a series of market forecasts and growth opportunities in order to help inform pharmaceutical decision-making, particularly in the areas of corporate planning, portfolio management and market forecasting.

The data and analysis contained within the report are comprehensive, consistent and up-to-date in order to provide a single-point reference for understanding key pharmaceutical market trends in 2007.

Headline Findings

The global pharmaceutical market is forecast to grow to US$897 billion in 2011, an equivalent CAGR of 6.9% over the next five years.
Strong growth in the 10 European markets that joined the European Union in 2004 will help to boost European sales over the next five years.
In 2006 the leading therapy areas by sales were cardiovascular with 14.2% share and CNS with 14.1%.
Continued double-digit market growth in China will make it the seventh biggest drug market by sales in 2010.
The top 100 blockbuster drugs generated sales of US$232.2 billion accounting for 36% of the total pharma market.
Total pharmaceutical sales from the top 10 companies accounted for more than 40% of the total market.

Key Features Of The Report

Comprehensive market trends for key countries, regions, therapy areas, products and companies.
Country profiles for leading pharma markets with market segment trends and 5 year forecasts.
Therapy area profiles for leading therapeutic classes and key products and 2010 sales forecasts.
Detailed profiles of 10 leading pharmaceutical products in 2006, including five year future sales forecasts.
Detailed profiles of 10 leading pharmaceutical companies in 2006, including 2011 sales forecasts.(AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson and Johnson, Merck & Co, Novartis, Pfizer, Roche, Sanofi-Aventis Wyeth)
173 pages long, with 87 figures and 67 tables to illustrate the market trends.

Use This Report To:

Benchmark your portfolio against key market trends and forecasts in order to plan better for success.
Identify key areas of pharmaceutical market growth and key opportunities for delivering successful sales growth over the next five years.
Support internal planning and decision-making with an external perspective founded on detailed analysis and transparent market forecasts.

Report Coverage

The report methodology provides a detailed but transparent analysis of key pharmaceutical market trends, including key markets, therapy areas, products and companies. Historical trends are formed over a three-year time horizon and future forecasts are made using a five-year future time period. Thus, the data and analysis relate to the nine-year time horizon from 2003 to 2011.

All data used in outlining historical trends is clearly sourced within the report and any data limitations or additional assumptions are explicitly detailed within the text of the report. Future market forecasts are projected based on both historical trends and future expectations over market conditions and events. The assumptions used to form the basis of key market forecasts are outlined in detail within the text of the report.

Content

Introduction
- Key global markets
- Key therapeutic markets
- Key products
- Key companies
- Key trends and opportunities
Chapter 1 Introduction
- Global pharmaceutical market
- Report overview
  - Methodology
  - Sources
  - Structure
Chapter 2 Key global markets
- Key pharmaceutical markets
- US pharmaceutical market
  - US purchasing channels
  - US retail drug market
  - US therapy areas
  - US market leaders
- European pharmaceutical market
  - European retail drug market
  - European therapy areas
- Japanese pharmaceutical market
  - Japanese therapy areas
Chapter 3 Key therapeutic markets
- Key therapy areas
  - Retail drug therapy areas
  - Cardiovascular therapy area
  - Cardiovascular markets
- Cardiovascular blockbusters
  - Central nervous system therapy area
  - Central nervous system markets
  - Central nervous system blockbusters
- Alimentary/ metabolism therapy area
  - Alimentary/ metabolism markets
  - Alimentary/ metabolism blockbusters
- Respiratory therapy area
  - Respiratory markets
  - Respiratory blockbusters
- Anti-infectives therapy area
  - Anti-infectives markets
  - Anti-infectives blockbusters
- Musculo-skeletal therapy area
  - Musculo-skeletal markets
  - Musculo-skeletal blockbusters
- Cytostatics therapy area
  - Cytostatics markets
  - Cytostatics blockbusters
Chapter 4 Key products
- Leading products
  - Lipitor (atorvastatin)
  - Advair/ Seretide (fluticasone/ salmeterol)
  - Plavix (clopidogrel)
  - Norvasc (amlodipine)
  - Nexium (esomeprazole)
  - Enbrel (etanercept)
  - Remicade (infliximab)
  - Zyprexa (olanzapine)
  - Prevacid (lansoprazole)
  - Diovan/ Co-Diovan/ Provas/ Miten (valsartan/ hydrochlorothiazide)
- Blockbuster trends
  - Blockbusters by drug type
  - Blockbusters by therapy area
  - Blockbusters by company
Chapter 5 Key companies
- Major pharmaceutical companies
  - Major company financials
  - Major company locations
- Top 10 pharmaceutical companies
  - Top 10 company financials
  - Top 10 company value drivers
- Leading pharmaceutical companies
  - Pfizer
  - GlaxoSmithKline
  - Sanofi-Aventis
  - Roche
  - AstraZeneca
  - Novartis
  - Johnson and Johnson
  - Merck & Co
  - Wyeth
  - Eli Lilly
Chapter 6 Key trends and opportunities
- Global market forecasts
  - The US market
  - The European market
  - The Japanese market
  - Other markets
- Key therapy area forecasts
  - Cardiovascular market
  - Central nervous system market
  - Alimentary/ metabolism market
  - Anti-infectives market
  - Respiratory market
  - Oncology market
- Key product forecasts
  - Lipitor (atorvastatin)
  - Advair/ Seretide (fluticasone/ salmeterol)
  - Plavix (clopidogrel)
  - Norvasc (amlodipine)
  - Nexium (esomeprazole)
  - Enbrel (etanercept)
  - Remicade (infliximab)
  - Zyprexa (olanzapine)
  - Prevacid (lansoprazole)
  - Diovan/ Co-Diovan (valsartan/ hydrochlorothiazide)
- Key company forecasts
  - Pfizer
  - GlaxoSmithKline
  - Sanofi-Aventis
  - Roche
  - AstraZeneca
  - Novartis
  - Johnson and Johnson
  - Merck & Co
  - Wyeth
  - Eli Lilly
Appendix
- Proprietary data sources
  - Product Trends Database
  - Company Trends Database
- Top 100 pharmaceutical products
- Top 62 pharmaceutical companies
Figures
- Figure 1: Global pharmaceutical market, 1999-2006
- Figure 2: Report structure
- Figure 3: Global pharmaceutical market share by region, 2006
- Figure 4: Global pharmaceutical market by region, 2003-2006
- Figure 5: US pharmaceutical market, 2003-2006
- Figure 6: US pharmaceutical market share by purchasing channel, 2006
- Figure 7: US pharmaceutical market by purchasing channel, 2003-2006
- Figure 8: US retail pharmaceutical market, 2003-2006
- Figure 9: US retail pharmaceutical market share by therapy area, 2006
- Figure 10: US retail pharmaceutical market by therapy area, 2003-2006
- Figure 11: Top 10 products by US pharmaceutical sales, 2006
- Figure 12: Top 10 companies by US pharmaceutical sales, 2006
- Figure 13: Top 10 companies by share of US pharmaceutical sales, 2006
- Figure 14: European pharmaceutical market, 2003-2006
- Figure 15: European pharmaceutical market share by country, 2006
- Figure 16: European top 5 retail pharmaceutical market, 2003-2006
- Figure 17: European top 5 retail pharmaceutical market share by country, 2006
- Figure 18: European top 5 retail pharmaceutical market by country, 2003-2006
- Figure 19: European top 5 retail pharmaceutical market share by therapy area, 2006
- Figure 20: European top 5 retail pharmaceutical market by therapy area, 2003-2006
- Figure 21: Japanese pharmaceutical market, 2003-2006
- Figure 22: Japanese pharmaceutical market share by therapy area, 2006
- Figure 23: Japanese pharmaceutical market by therapy area, 2003-2006
- Figure 24: Global pharmaceutical market by therapy area, 2006
- Figure 25: Top 10 product classes by global pharmaceutical sales, 2006
- Figure 26: Global retail pharmaceutical market share by therapy area, 2006
- Figure 27: Global retail pharmaceutical market by therapy area, 2003-2006
- Figure 28: Cardiovascular retail pharmaceutical market, 2003-2006
- Figure 29: Cardiovascular retail pharmaceutical market share by country, 2006
- Figure 30: Cardiovascular retail pharmaceutical market by country, 2003-2006
- Figure 31: Central nervous system retail pharmaceutical market, 2003-2006
- Figure 32: Central nervous system retail pharmaceutical market share by country, 2006
- Figure 33: Central nervous system retail pharmaceutical market by country, 2003-2006
- Figure 34: Alimentary/ metabolism retail pharmaceutical market, 2003-2006
- Figure 35: Alimentary/ metabolism retail pharmaceutical market share by country, 2006
- Figure 36: Alimentary/ metabolism retail pharmaceutical market by country, 2003-2006
- Figure 37: Respiratory retail pharmaceutical market, 2003-2006
- Figure 38: Respiratory retail pharmaceutical market share by country, 2006
- Figure 39: Respiratory retail pharmaceutical market by country, 2003-2006
- Figure 40: Anti-infectives retail pharmaceutical market, 2003-2006
- Figure 41: Anti-infectives retail pharmaceutical market share by country, 2006
- Figure 42: Anti-infectives retail pharmaceutical market by country, 2003-2006
- Figure 43: Musculo-skeletal retail pharmaceutical market, 2003-2006
- Figure 44: Musculo-skeletal retail pharmaceutical market share by country, 2006
- Figure 45: Musculo-skeletal retail pharmaceutical market by country, 2003-2006
- Figure 46: Cytostatics retail pharmaceutical market, 2003-2006
- Figure 47: Cytostatics retail pharmaceutical market share by country, 2006
- Figure 48: Cytostatics retail pharmaceutical market by country, 2003-2006
- Figure 49: Blockbuster drug sales share by drug type, 2006
- Figure 50: Blockbuster drug sales share by lifecycle stage, 2006
- Figure 51: Blockbuster drug sales share by therapy area, 2006
- Figure 52: Blockbuster drug sales share by company, 2006
- Figure 53: Major companies pharmaceutical sales, 2004-2006
- Figure 54: Major companies revenue share allocation, 2006
- Figure 55: Major companies revenue allocation, 2004-2006
- Figure 56: Major companies pharmaceutical sales by location, 2006
- Figure 57: Top 10 pharma companies pharmaceutical sales, 2004-2006
- Figure 58: Top 10 pharma companies by global pharmaceutical sales, 2006
- Figure 59: Top 10 biotechnology companies by global revenues, 2006
- Figure 60: Top 10 pharma companies revenue share allocation, 2006
- Figure 61: Top 10 pharma companies revenue allocation, 2004-2006
- Figure 62: Key value drivers for top 10 pharma companies (income), 2006
- Figure 63: Key value drivers for top 10 pharma companies (sales), 2006
- Figure 64: Key value drivers for top 10 pharma companies (sales/ R&D), 2006
- Figure 65: Pfizer therapy area sales, 2004-2006
- Figure 66: GlaxoSmithKline therapy area sales, 2004-2006
- Figure 67: Sanofi-Aventis blockbuster therapy area sales, 2004-2006
- Figure 68: Roche therapy area sales, 2004-2006
- Figure 69: AstraZeneca therapy area sales, 2004-2006
- Figure 70: Novartis therapy area sales, 2004-2006
- Figure 71: Johnson and Johnson blockbuster therapy area sales, 2004-2006
- Figure 72: Merck & Co blockbuster therapy area sales, 2004-2006
- Figure 73: Wyeth blockbuster therapy area sales, 2004-2006
- Figure 74: Eli Lilly therapy area sales, 2004-2006
- Figure 75: Global pharmaceutical market forecast, 2003-2011
- Figure 76: Global pharmaceutical market forecast by regions, 2003-2010
- Figure 77: Top 10 pharmaceutical drugs by forecast sales, 2011
- Figure 78: Lipitor (atorvastatin) forecast sales, 2003-2011
- Figure 79: Advair/ Seretide (fluticasone/ salmeterol) forecast sales, 2003-2011
- Figure 80: Plavix (clopidogrel) forecast sales, 2003-2011
- Figure 81: Norvasc (amlodipine) forecast sales, 2003-2011
- Figure 82: Nexium (esomeprazole) forecast sales, 2003-2011
- Figure 83: Enbrel (etanercept) forecast sales, 2003-2011
- Figure 84: Remicade (infliximab) forecast sales, 2003-2011
- Figure 85: Zyprexa (olanzapine) forecast sales, 2003-2011
- Figure 86: Prevacid (lansoprazole) forecast sales, 2003-2011
- Figure 87: Diovan/ Co-Diovan (valsartan/ hydrochlorothiazide) forecast sales, 2003-2011
Tables
- Table 1: Global pharmaceutical market trends by region, 2004-2006
- Table 2: US pharmaceutical market trends by purchasing channel, 2004-2006
- Table 3: US retail pharmaceutical market trends by therapy area, 2003-2006
- Table 4: Top 10 products trends by US pharmaceutical sales, 2004-2006
- Table 5: European top 5 retail pharmaceutical market trends by country, 2004-2006
- Table 6: European top 5 retail pharmaceutical market trends by therapy area, 2004-2006
- Table 7: Japanese pharmaceutical market trends by therapy area, 2004-2006
- Table 8: Top 10 product classes trends by global pharmaceutical sales, 2005-2006
- Table 9: Global retail pharmaceutical market trends by therapy area, 2004-2006
- Table 10: Cardiovascular retail pharmaceutical market trends by country, 2004-2006
- Table 11: Cardiovascular blockbuster drug sales, 2004-2006
- Table 12: Central nervous system retail pharmaceutical market trends by country, 2004-2006
- Table 13: Central nervous system blockbuster drug sales, 2004-2006
- Table 14: Alimentary/ metabolism retail pharmaceutical market trends by country, 2004-2006
- Table 15: Alimentary/ metabolism blockbuster drug sales, 2004-2006
- Table 16: Respiratory retail pharmaceutical market trends by country, 2004-2006
- Table 17: Respiratory blockbuster drug sales, 2004-2006
- Table 18: Anti-infectives retail pharmaceutical market trends by country, 2004-2006
- Table 19: Anti-infectives blockbuster drug sales, 2004-2006
- Table 20: Musculo-skeletal retail pharmaceutical market trends by country, 2004-2006
- Table 21: Musculo-skeletal blockbuster drug sales, 2004-2006
- Table 22: Cytostatics retail pharmaceutical market trends by country, 2004-2006
- Table 23: Cytostatics blockbuster drug sales, 2004-2006
- Table 24: Top 20 products by global pharmaceutical sales, 2004-2006
- Table 25: Lipitor (atorvastatin) profile, 2006
- Table 26: Advair/ Seretide (fluticasone/ salmeterol) profile, 2006
- Table 27: Plavix (clopidogrel) profile, 2006
- Table 28: Norvasc (amlodipine) profile, 2006
- Table 29: Nexium (esomeprazole) profile, 2006
- Table 30: Enbrel (etanercept) profile, 2006
- Table 31: Remicade (infliximab) profile, 2006
- Table 32: Zyprexa (olanzapine) profile, 2006
- Table 33: Prevacid/ Zoton (lansoprazole) profile, 2006
- Table 34: Diovan/ Co-Diovan/ Provas/ Miten (valsartan/ hydrochlorothiazide) profile, 2006
- Table 35: Top 10 blockbuster products by global pharmaceutical sales growth, 2004-2006
- Table 36: Top 10 blockbuster products by declining global pharmaceutical sales, 2004-2006
- Table 37: New blockbuster products, 2004-2006
- Table 38: Major companies revenue allocation trends, 2004-2006
- Table 39: Top 10 pharma companies by global pharmaceutical sales, 2004-2006
- Table 40: Top 10 biotechnology companies by global revenues, 2004-2006
- Table 41: Top 10 pharma companies revenue allocation trends, 2004-2006
- Table 42: Pfizer profile, 2006
- Table 43: Pfizer blockbuster sales, 2004-2006
- Table 44: GlaxoSmithKline profile, 2006
- Table 45: GlaxoSmithKline blockbuster sales, 2004-2006
- Table 46: Sanofi-Aventis profile, 2006
- Table 47: Sanofi-Aventis blockbuster sales, 2004-2006
- Table 48: Roche profile, 2006
- Table 49: Roche blockbuster sales, 2004-2006
- Table 50: AstraZeneca profile, 2006
- Table 51: AstraZeneca blockbuster sales, 2004-2006
- Table 52: Novartis profile, 2006
- Table 53: Novartis blockbuster sales, 2004-2006
- Table 54: Johnson and Johnson profile, 2006
- Table 55: Johnson and Johnson blockbuster sales, 2004-2006
- Table 56: Merck & Co profile, 2006
- Table 57: Merck & Co blockbuster sales, 2004-2006
- Table 58: Wyeth profile, 2006
- Table 59: Wyeth blockbuster sales, 2004-2006
- Table 60: Eli Lilly profile, 2006
- Table 61: Eli Lilly blockbuster sales, 2004-2006
- Table 62: Global pharmaceutical market forecast by regions, 2003-2011
- Table 63: Global pharmaceutical market forecast by therapy area, 2006-2011
- Table 64: Top 10 pharmaceutical drugs forecast, 2003-2011
- Table 65: Top 10 pharmaceutical companies forecast, 2006-2011
- Table 66: Top 100 products by global pharmaceutical sales, 2004-2006
- Table 67: Top 62 companies by global pharmaceutical sales, 2004-2006